AACR 2022: YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy

AACR 2022: YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy

Conclusions

• YH012 is a novel bispecific HER2/TROP2 antibody-drug conjugate (BsAb-ADC) developed using the RenLite^TM platform.
• The TAAs HER2 and TROP2 are highly co-expressed in a variety of solid tumors, implying multiple potential indications for YH012.
• Bispecificity of YH012 enhances selective endocytic uptake of BsAbs into HER2/TROP2 co-expressing
  tumor cells resulting in enrichment of anti-mitotic payload (MMAE) delivery and enhanced anti-tumor efficacy compared to controls.
• The backbone of YH012 was constructed using RenLite^TM mice and the preexisting “knobs-into-holes” (KiH) heterodimerization method, demonstrating the value of this workflow to for rapidly generating BsAb-ADCs of unequaled purity, stability, and functional potential.